Fluorescence in situ hybridization (FISH) was performed in 17 myeloid leukemia patients and seven lymphoid leukemia/ lymphoma patients who exhibited chromosomal abnormalities on the short arm of chromosome 17, in order to detect a commonly deleted region on chromosome band 17p13. Twenty-four leukemia/lymphoma patients studied cytogenetically at our institution over a period of 10 years had detectable 17p abnormalities such as translocation (six patients), addition (11 patients) and deletion of 17p13 (seven patients). A 17p abnormality was the only abnormality present in three patients. Most of the patients had additional complex cytogenetic abnormalities. The diagnosis was acute myeloid leukemia (AML) in 10 patients, two each with chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and myelodysplastic syndrome (MDS) and the remaining three with malignant lymphoma (ML). Seven cosmid probes (D17S34, cCl17-624, cCl17-453, D17S379, cCl17-636, cCl17-732 and TP53) which mapped on 17p13 were used to analyze the allelic deletion. Eighty percent (19 out of 24) of the informative leukemia patients exhibited allelic loss in 17p13.3 at cC17-624. The smallest region of an overlapping deletion was observed on chromosome band 17p13.3 between cCl17-624 and cCl17-453. Patients with transloation involving 17p also showed deletion at cCl17-624 and cCl17-453. We hypothesize that this region contains a novel tumor suppressor gene(s) that is involved in leukemogenesis.
Introduction
Molecular studies on genetic loss have, to date, focused on deletions involving the long arm of chromosomes 5, 6, 7, 13 and 20 and the short arm of chromosomes 9 and 17, in hematological malignancies. 1 In most of these cases, however, the molecular events that are relevant for the pathogenesis of the disorder are unknown. The incidence of deletion of chromosome arm 17p is 6.0% in acute myeloid leukemia (AML), 4.2% in myelodysplastic syndrome (MDS), 9.4% in myeloproliferative disorder (MPD), 2.0% in acute lymphoblastic leukemia (ALL) and 4.8% in lymphoproliferative disorder (LPD). 1 Complete or partial loss of the short arm of chromosome 17 resulted from simple deletion, unbalanced translocation, isochromosome or monosomy. The short arm of chromosome 17 was shown to contain putative tumor suppressor genes in addition to the TP53 gene. 2, 3 Abnormalities of chromosome arm 17p were frequently detected during leukemia progression of MDS, chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML). [4] [5] [6] The increased incidence of 17p loss in relapse appears to be a feature of the late stage
The loss of material from the short arm of chromosome 17 is frequent in AML and MPD, whether other genes on 17p may be of importance has not been invested. In the present study we attempted to find a commonly deleted region on chromosome band 17p13 in various leukemia/lymphoma patients having abnormalities at 17p. Twenty-four patients were analyzed by interphase and metaphase FISH methods using seven 17p13 locus probes (D17S34, cCl17-624, cCl17-453, D17S379, cCl17-636, cCl17-732 and TP53). FISH deletion mapping analysis allowed us to detect the smallest region of an overlapping deletion on 17p13.3.
Materials and methods

Patients
Bone marrow/lymph node samples of 24 leukemia/lymphoma patients who exhibited aberrations at chromosome arm 17p were analyzed in this study. Out of the 24 patients, 17 were myeloid and seven lymphoid leukemias. The fixed bone marrow and lymph node cells were stored at −20°C following their use for conventional cytogenetic analysis since 1986. All the samples were obtained at the stages of diagnosis and relapse.
Cytogenetic analysis
The bone marrow and lymph node cells were subjected to unstimulated 24-h culture using a standard protocol.
14 Metaphase slides were prepared and treated for G-banding using trypsin treatment. Chromosome identification and karyotyping were performed as described by the ISCN 1995. 15 Fluorescence in situ hybridization (FISH) Bone marrow and lymph node cell suspensions in Carnoy's fixative, which had been stored at −20°C after cytogenetic analysis, were studied by FISH, essentially as described by us previously. 16 Seven 17p locus probes D17S34, D17S379, TP53 (Oncor, Gaithersburg, MD, USA) and cCl17-624, cCl17-636, cCl17-453, cCl17-732 17 (obtained from the Japanese Gene Bank) were individually hybridized with fixed cells at 37°C for 48-72 h in a moist chamber. After hybridization, the slides were washed with 50% formamide in 2 × SSC (43°C; 10 min) and with 2 × SSC (37°C; 10 min). The D17S34, D17S379 and TP53 probes were digoxigenin-labeled and detected with antidigoxigenin rhodamine Fab fragments (Boehringer, Mannheim, Germany) producing red signals. The cCl17-624, cCl17-636, cCl17-453 and cCl17-732 probes were labeled with biotin-14-dATP using a nick translation kit (GIBCO BRL, Gaithersburg, MD, USA). These probes were detected with fluorescein isothiocyanate (FITC)-conjugated avidin (Oncor), and amplified with anti-avidin-FITC (Oncor) producing green signals. Digoxigenin-labeled probes were counterstained with 4′6-diamidino-2-phenyl indole dihydrochloride (DAPI) (5 ng/ml; Sigma, St Louis, MO, USA) and biotin-labeled probes with propidium iodide (Oncor).
The interphase and metaphase signals were scored under a fluorescent microscope fitted with appropriate absorption and excitation filters (Olympus, Tokyo, Japan). For all probes, the cells with two signals were scored as intact except in the case of D17S379, which contained the RARA chromosome 17 control probe, for which the cells with four signals were scored as intact. When necessary, the signals generated were confirmed using a laser scanning microscope (Olympus). Two independent observers scored the signals generated in the cells without prior knowledge of the probe/sample used.
Only those cells in which the signals were of regular size and intensities were accepted for the study. Overlapping nuclei were not scored. Split signals were counted as one and non-specific signals were omitted. Patients showing deletion of a locus as determined by interphase FISH was also analyzed by metaphase FISH.
Controls
The cut-off values for the FISH analysis were determined from 10 samples of bone marrow and lymph node cultures from cytogenetically normal persons. FISH with D17S34, TP53, cCl17624, cCl17-636, cCl17-453 and cCl17-732 showed one signal in 3.0 ± 1.15, 2.4 ± 0.96, 3.0 ± 0.81, 4.0 ± 0.81, 2.3 ± 0.67, 3.0 ± 0.94% of control cells, respectively. The presence of a deletion was defined as the detection of more than 6.45, 5.28, 5.43, 6.43, 4.31 and 5.82% (mean ± 3 s.d.) of cells with a single signal, respectively. FISH with D17S379 detected three signals in 3.6 ± 0.84% of control cells. The presence of a deletion was defined as the detection of more than 6.12% (mean ± 3 s.d.) of cells with three signals.
Results
Cytogenetic findings
The karyotype results of all patients studied is shown in Table 1 . Of the 24 leukemia/lymphoma patients analyzed, a 17p abnormality was the only abnormality in three patients (patient Nos. 2, 6 and 14). Lymphoid leukemia/lymphoma patients exhibited complex karyotypes. Addition of an unknown band at 17p13 was seen in 11 patients. Six patients exhibited translocation involving 17p. The partner chromosomes were chromosome arm 9q in two patients and one each of chromosome arms 1p, 11q, 13p and 21q. The remaining seven patients showed deletion at 17p13. Of 18 patients exhibiting translocation and addition involving 17p, the breakpoint was at 17p13 in 16 patients and 17p11 in two patients.
FISH results
FISH results are summarized in Figure 1 and Table 2 . Of the 24 patients, only three showed deletion of the TP53 gene. The TP53 gene was intact in all of the lymphoid leukemia/lymphoma patients studied. Fourteen out of 17 (82.3%) myeloid leukemia patients showed two signals of the TP53 probe. The TP53 gene was deleted in AML M3 (patient No. 6), in which addition of an unknown band at 17p13 was observed. For the remaining patients exhibiting TP53 gene deletions (patient Nos 7 and 8) the FISH results were same as those of the conventional cytogenetics analysis. The cosmid locus cCl17-732 was intact in all the patients in which the TP53 gene was intact, except in patient No. 6 in whom only a TP53 gene deletion was observed. Locus cCl17-636, which is located on 17p13.2, was deleted in four out of 24 patients (16.7%). On the other hand, the four loci on 17p13.3, D17S34, cCl117-624, cCl17-453 and D17S379, showed deletions of 66, 79, 75 and 66%, respectively. Table 3 represents the number of interphase and metaphase nuclei analyzed in each patient using seven 17p13 locus probes. Loci cCl17-624 and cCl17-453 had a highest percentage of allelic loss at 79 and 75%, respectively. Interestingly, 66.7% of the patients (12 out of 18) with translocation and addition at 17p had deletions at the same region. Fourteen out of 17 (82.4%) patients with the myeloid phenotype had allelic loss at cCl17-624 and five out of seven (71.4%) with the lymphoid phenotype at cCl17-624. A deleted region spanning cCl17-624 and cCl17-453 was common in myeloid leukemia and lymphoid leukemia/lymphoma.
Discussion
We performed FISH analysis and deletion mapping of chromosome band 17p13 using seven probes for 17p13 to find common region of deletion in 24 leukemia/lymphoma patients who had aberrations at chromosome arm 17p. The smallest common region of an overlapping deletion was observed on 17p13.3 between the cCl17-624 and cCl17-453 loci. Seventy-nine percent of leukemia/lymphoma patients studied showed the allelic deletion for the marker distal to the TP53 gene and that many retained the TP53 gene at 17p13.1. There have been few studies on LOH analysis in leukemia patients because it is difficult to obtain control samples as normal counterparts of leukemic cells. Thus, in this study we exploited the high sensitivity of the FISH technique to detect the loss of various loci on 17p13.3. The FISH results are very accurate and using FISH one can avoid technical errors occurring in PCR. By using FISH it is very easy to decide whether a locus is lost. Hence, we believe that FISH is an appropriate method for performing deletion mapping in leukemia patients.
The deletion of the 17p13.3 region independent of TP53 gene deletion has been observed in solid tumors. The LOH on chromosome arm 17p was shown in a wide range of solid tumors. [9] [10] [11] [12] [13] Eighty percent of informative ovarian tumors exhibited allelic loss in 17p13.3 at D17S30 and D17S28 or both loci within this region. Breast cancer has a LOH rate of 51-61% at D17S30. A common region of deletion at 17p13.3 for breast cancer was flanked by D17S34 and D17S510, 18 a distance of 19.2 cM. The deletion panel for our common region showed an overlapping deletion at cCl17-624 and cCl17-453. A variable number of tandem repeats (VNTR) at loci D17S30 and D17S28 are situated in-between loci cCl17-624 and cCl17-453. We assumed that the alleles in these 19 and the CRK proto-oncogene were mapped as potential cancer genes. 20 All these genes except PEDF are located in-between D17S28 and D17S30 VNTR regions, whereas PEDF is located at 17p13.1. Recently, tumor suppressor genes OVCA1 and OVCA2 were mapped to chromosome band 17p13.3, spanning approximately 20 kb of genomic DNA and located between PYNZ-22 and PYNH37.3.
We also performed PCR analysis of the VNTR regions PYNZ-22 21 and AKG2-1 3 . Amplification by PCR of a highly polymorphic VNTR segment, PYNZ-22, showed a heterozygosity of 86%. 21 On the other hand, 80% of our samples showed a single band when this region was amplified by PCR. However we do not know which patient is homozygous for this allele. Because of the inherent difficulties in analyzing the VNTR regions in hematological malignancies we could not present the data here. Little is known about the newly identified VNTR locus, AKG2-1. Since this region is very close to cCl17-624, we assume that this region might have also been deleted in our patients.
Several reports are available on chromosome arm 17p loss and inactivation or mutation of the TP53 gene in leukemia patients. 4, 5, 7, [22] [23] [24] [25] In these reports the leukemogenesis was correlated to TP53 gene mutation, although a few percentages of such patients showed mutation of this gene. The mechanism of tumor progression was said to be associated with abnormalities of short arm of chromosome 17 leading to LOH or deletion of one TP53 and dysfunctioning of the remaining TP53 allele. In the present study only three patients had loss of TP53 allele out of 24 analyzed. Therefore, the mechanism of anti-oncogene-mediated tumorigenesis 25 is not the result of the progression of the disease in our patients studied. Moreover the finding of previous data (summarized by Giovanna Rege-Cambrin et al 26 in Table 2 ) shows that the isochromosomes i(17q) was only occasionally coincidental with inactivation of the residual TP53 allele. So, our conclusion is in agreement with Giovanna Rege-Cambrin et al 26 that the TP53 inactivation event seems to be limited to a minority of leukemia patients with 17p abnormalities. This leads to the investigation of new tumor suppressor gene(s) associated with the progression of leukemia.
Of our 24 patients, eight (patients Nos 7, 8, 9, 16, 17, 18, 20 and 21) showed the 17p13 deletion as determined by conventional cytogenetic analysis. However, when we performed FISH, all these patients retained three loci on 17p13.1 and 17p13.2 including the TP53 gene locus except in patients Nos example is deletion of TEL gene on chromosome arm 12p in childhood ALL with t(12;21). 27 Similarly, allelic loss of TP53 gene was reported in patients with Sézary syndrome during the formation of i(17q) in two patients and add(17p) in one patient. 28 We suggest a similar mechanism to our patients leading to a common region of deletion on chromosome arm 17p. In patient No. 16, a terminal deletion of two loci and an interstitial deletion of D17S379 was observed. The same pattern of deletion was observed in patient No. 6 with an interstitial deletion of TP53 gene, a feature that had not been identified by conventional cytogenetics. A similar interstitial deletion pattern was reported in NHL patients with two separate regions of deletions on the long arm of chromosome 6. 29 Two patients (patient Nos 3 and 24) with +add(17) also showed single signal for the telomeric probes by FISH, a feature common in solid tumors. 30 The allelic deletion at D17S34, cCl17-624, cCl17-453 and D17S379 was observed in 64, 82, 71 and 64% respectively, of the patients with myeloid malignancies, whereas in lymphoid leukemia/lymphoma there was 71% of allelic loss in all four loci D17S34, cC17-624, cC17-453 and D17S379. Our results support the hypothesis of Philips et al 31 that there might be a new oncogene(s), located on the commonly deleted region and it may have an important role in the progression of leukemia/lymphoma. The use of molecular techniques to detect the loss of heterozygosity of the short arm of chromosome 17 in a larger series of patients and the investigation of the role of the commonly deleted region would be of great significance in understanding the disease progression.
